ROCKET PHARMACEUTICALS, INC. Earnings Per Share Disclosure
Basic and diluted net loss per share attributable to common stockholders was calculated as follows:
|
For the Years Ended December 31, |
|
||||
|
2025 |
|
2024 |
|
||
Numerator: |
|
|
|
|
||
Net loss attributable to common stockholders |
$ |
(223,123 |
) |
$ |
(258,746 |
) |
Denominator: |
|
|
|
|
||
Weighted-average common shares outstanding - basic and diluted |
|
111,123,770 |
|
|
94,807,773 |
|
Net loss per share attributable to common stockholders - basic and diluted |
$ |
(2.01 |
) |
$ |
(2.73 |
) |
For the years ended December 31, 2025 and 2024, the Company included the 3,126,955 potential shares from the pre-funded warrants acquired by RTW in 2023 and the 400,000 potential shares from the pre-funded warrants acquired by RTW in 2024 in the basic weighted-average common shares outstanding as it only requires the holder to pay $0.01 per share upon exercise.
The Company excluded the following potential shares of common stock, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:
|
For the Years Ended December 31, |
|
||||
|
2025 |
|
2024 |
|
||
Warrants exercisable for common shares |
|
1,971,073 |
|
|
2,588,123 |
|
Restricted stock units |
|
5,000,566 |
|
|
1,414,210 |
|
Performance stock units |
|
- |
|
|
69,661 |
|
Options to purchase common shares |
|
12,163,019 |
|
|
16,044,686 |
|
Total potential shares excluded from diluted net loss per share |
|
19,134,658 |
|
|
20,116,680 |
|
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Feb 26, 2026 | Showing above |
| 2024 | Feb 27, 2025 | |
| 2023 | Feb 27, 2024 | |
| 2022 | Feb 28, 2023 | |
| 2021 | Feb 28, 2022 | |
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.